WHO. Cancer .2018 .. , : .
.2019 .. U.S. Breast Cancer Statistics, 2 : .
Sultana S,Akhtar N,Rehman JU,Rehman RU . .. [cited 2019 July, 20 : .
Prevalence .2014 .risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev, 15(11) : 4411-6.
Cancer Cancer.net. Breast .2015 .Management of patients with hormone receptorpositive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res, 7 : 37-46.
DA Yardley .2010 .Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer, 10(1) : 64-73.
Imamura M,Morimoto T,Nomura T,Michishita S,Nishimukai A,Higuchi T . .independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. , : .
.2018 .. World J Surg Oncol, 16(1) : 26.
Bahrami-Ahmadi A,Makarian F,Mortazavizadeh MR,Yazdi MF,Chamani M. .2012 .Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients. J Res Med Sci, 17(9) : 850-4.
Dong Y,Hou H,Wang C,Li J,Yao Q,Amer S .2015 .The Diagnostic Value of 18F-FDG PET/CT in Association with Serum Tumor Marker Assays in Breast Cancer Recurrence and Metastasis. Biomed Res Int, : 489021.
Laessig D,Nagel D,Heinemann V,Untch M,Kahlert S,Bauerfeind I .2007 .Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res, 27(4A) : 1963-8.
Cronin-Fenton D,Kjaersgaard A,Norgaard M,Amelio J,Liede A,Hernandez RK .2018 .Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat, 167(2) : 517-28.
Fejzic H,Mujagic S,Azabagic S,Burina M. .2015 .Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad, 44(1) : 39-46.
Ghoncheh M,Pournamdar Z,Salehiniya H .2016 .Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev, 17(S3) : 43-6.
Berruti A,Tampellini M,Torta M,Buniva T,Gorzegno G,Dogliotti L .1994 .Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer, 30a(14) : 2082-4.
Taghizadeh A,Pourali L,Joudi M,Salehi M,Eshghi S,Torabian F .2019 .Assessment of Elevated Serum Tumor Markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3) among Patients with Different Subtypes of Metastatic Breast Cancer. Middle East J Cancer, 10(1) : 17-22.
Ali HQ,Mahdi NK,Al-Jowher MH .2013 .The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. J Pak Med Assoc, 63(9) : 1138-41.
Nieder C,Dalhaug A,Haukland E,Mannsaker B,Pawinski A .2017 .Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. J Clin Med Res, 9(3) : 183-7.
Fatima H,Maqbool A,Siddiqui M,Haider G,Sohail H,Saleem O .2016 .Significance of Tumor Marker CA15-3 in Metastatic Breast Cancer. J Cancer Tumor Int, 4(3) : 1-12.
Shao Y,Sun X,He Y,Liu C,Liu H. Elevated C .2015 .Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS One, 10(7) : e0133830.
Osman AM,Hamid ME,Satti AH,Goreish IA .2016 .High Concentration of Tumor Marker Cancer Antigen CA15-3 in Breast CancerPatients after Surgery. Breast Cancer Curr Res, 1(114) : 2.
Darlix A,Lamy PJ,Lopez-Crapez E,Braccini AL,Firmin N,Romieu G .2016 .Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer, 16 : 428.
Hosseini SM,Razmjoo S,Arvandi SH,Barat T. CEA .2015 .3 Serum Level in Metastatic Breast Cancer and its Correlation with Distant Metastasis. Age, 500(40) : 37.